Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gammagard IVIg in mild to moderate Alzheimer's disease
NCT00299988Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Feb 2006
- Primary completion
- Jan 2009
- Countries
- 1
01
Overview
A Phase 2 trial of intravenous immunoglobulin G in Alzheimer's disease (AD), sponsored by Weill Cornell Medicine. Started Feb 2006; status: terminated.
02
Drugs
intravenous immunoglobulin G
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00299988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00299988.